Golimumab Pharmacokinetics After Repeated Subcutaneous and Intravenous Administrations in Patients with Rheumatoid Arthritis and the Effect of Concomitant Methotrexate: An Open-Label, Randomized Study
Authors:
- Zhenhua XuZXZhenhua Xu
- Bart FrederickBFBart Frederick
- Dick E. de VriesDVDick E. de Vries
- Joyce A. FordJFJoyce A. Ford
- Monica KeenMKMonica Keen
- Mittie K. DoyleMDMittie K. Doyle
- Kevin J. PettyKPKevin J. Petty
- Hugh M. DavisHDHugh M. Davis
- Honghui ZhouHZHonghui Zhou
- 1 January 2012
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 34 (1) , 77-90
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Applications of a planar electrochemiluminescence platform to support regulated studies of macromolecules: Benefits and limitations in assay rangeJournal of Pharmaceutical and Biomedical Analysis, 2010
- Golimumab, a new human anti–tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty‐eight–week efficacy and safety results of a phase III randomized, double‐blind, placebo‐controlled studyArthritis & Rheumatism, 2010
- Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active rheumatoid arthritis: Twenty‐four–week results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study of golimumab before methotrexate as first‐line therapy for early‐onset rheumatoid arthritisArthritis & Rheumatism, 2009
- Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD StudyAnnals of the Rheumatic Diseases, 2009
- The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatmentArthritis & Rheumatism, 2005
- Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2005
- C‐reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: Defining subtypes of nonresponse and subsequent response to etanerceptArthritis & Rheumatism, 2005
- ROLE OF CYTOKINES IN RHEUMATOID ARTHRITISAnnual Review of Immunology, 1996
- Tumour necrosis factor in synovial exudates.Annals of the Rheumatic Diseases, 1988
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988